Weight loss drug Wegovy cuts risk of serious heart problems, company says | The Hill Skip to content This image provided by Novo Nordisk shows packaging for the company’s Wegovy drug. (Novo Nordisk via AP) Obesity drug Wegovy cut the risk of serious heart problems by 20 percent, the manufacturer announced Tuesday, results that could […]
Considering the positive data, Novo Nordisk is planning to file for Wegovy’s label expansion in both the US and the European Union (EU) in 2023. Image Credit: Maurice NORBERT / Shutterstock. Denmark-based Novo Nordisk has announced results from a Phase III cardiovascular clinical trial, where its lead obesity drug Wegovy (2.4mg subcutaneous semaglutide) showed a […]
Getty Images By Laura Foster Health, Science and Environment Reporter A weight-loss drug has been proven to also reduce the risk of a stroke or heart attack, according to a new trial. The makers of Wegovy say it cuts risk of a cardiovascular event in overweight people with heart disease by a fifth. The injection […]
The blockbuster obesity drug Wegovy cuts the risk of cardiovascular events, such as heart attack and stroke, by 20%, drugmaker Novo Nordisk said Tuesday. The findings are the first to demonstrate that a weight-loss drug has medical benefits beyond weight reduction. The results may be compelling enough to get insurance companies to provide coverage, said […]
Credit: iStock Use of semaglutide 2.4 mg (Wegovy) was associated with a reduction in the risk of major adverse cardiovascular events in the SELECT trial, according to an announcement from Novo Nordisk.1 Announced on August 8, 2023, topline results of the trial indicate once-weekly semaglutide 2.4 mg was associated with a 20% reduction in major […]
Cardiovascular diseases (CVD), particularly stroke and ischemic heart disease, remain the most common causes of premature death globally. The high incidence of CVD has been attributed to unhealthy lifestyles and obesity. Several other factors including smoking, adverse lipid profile, and elevated blood pressure also increase the risk of CVD events. In fact, the presence of […]
Credit: boonchai wedmakawand/Getty Images Topline results from the large-scale Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical study released today show that the Novo Nordisk obesity drug reduces the risk of major adverse cardiovascular events by 20 percent. The SELECT trial is the first to demonstrate the long-term […]
Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Weight loss jabs can reduce the risk of a heart attack or stroke in obese people with cardiovascular disease by a fifth, researchers claim. Pharmaceutical company Novo Nordisk conducted a five-year study […]
A clinical trial was the first to demonstrate that a new obesity drug could also improve patients’ heart health. A new obesity drug, Wegovy, slashed the risk of serious heart problems by 20 percent in a large trial, the drug’s maker said on Tuesday, a finding that could put pressure on insurers to cover the […]
Novo Nordisk A/S, a leading Danish pharmaceutical company, has achieved a groundbreaking milestone with its obesity medication Wegovy. A highly anticipated study has revealed that Wegovy not only effectively addresses weight concerns but also significantly reduces the risk of heart attacks and strokes among individuals with a history of heart issues. This unexpected development has […]